Richard L Clayton

US Patent:

20210363203, Nov 25, 2021

Filed:

Apr 5, 2021

Appl. No.:

17/222531

Inventors:

- Rockville MD, US
Richard S. Clayton - Rockville MD, US
Melissa E. Winn - Rockville MD, US

International Classification:

C07K 14/47
A61K 38/17
C12P 21/00

Abstract:

Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.

US Patent:

20200325190, Oct 15, 2020

Filed:

Jun 9, 2020

Appl. No.:

16/896213

Inventors:

Humcha K. Hariprakasha - Rockville MD, US
Richard S. Clayton - Rockville MD, US
Melissa E. Winn - Rockville MD, US

International Classification:

C07K 14/47
A61K 38/17
C12P 21/00

Abstract:

Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.

US Patent:

20190337999, Nov 7, 2019

Filed:

May 20, 2019

Appl. No.:

16/416268

Inventors:

- Rockville MD, US
Humcha K. Hariprakasha - Rockville MD, US
Richard S. Clayton - Rockville MD, US
Melissa E. Winn - Rockville MD, US

International Classification:

C07K 14/47
A61K 38/17
C12P 21/00

Abstract:

Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.

US Patent:

20160362462, Dec 15, 2016

Filed:

Jul 17, 2016

Appl. No.:

15/212277

Inventors:

- Rockville MD, US
Humcha K. Hariprakasha - Rockville MD, US
Richard S. Clayton - Rockville MD, US
Melissa E. Winn - Rockville MD, US

Assignee:

Therabron Therapeutics, Inc. - Rockville MD

International Classification:

C07K 14/47
C12P 21/00

Abstract:

Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.

US Patent:

20140275477, Sep 18, 2014

Filed:

Mar 15, 2013

Appl. No.:

13/843773

Inventors:

- Rockville MD, US
Humcha K. Hariprakasha - Rockville MD, US
Richard S. Clayton - Rockville MD, US
Melissa E. Winn - Rockville MD, US

Assignee:

CLARASSANCE, INC. - Rockville MD

International Classification:

C07K 14/47

US Classification:

530324

Abstract:

Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.